{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:16:29Z","timestamp":1783487789867,"version":"3.55.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n            <jats:title>Aim<\/jats:title>\n            <jats:p>The aim of this study was to assess the efficacy and safety of <jats:sup>177<\/jats:sup>Lu-DOTATATE in patients with neuroendocrine tumors (NETs) and extensive bone metastases, that is, more than 50% of the skeleton involved.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method<\/jats:title>\n            <jats:p>A single-center retrospective analysis was performed in 30 patients (13 women and 17 men, mean age, 60 years; range, 35\u201377 years) undergoing <jats:sup>177<\/jats:sup>Lu-DOTATATE therapy. Patients had progressive metastatic NETs with extensive skeletal metastases (&gt;50% skeletal involvement seen on baseline <jats:sup>68<\/jats:sup>Ga-DOTATATE PET\/CT). The average administered activity was 7.308 (SD, 0.02) GBq per cycle with average treatment interval of 15 weeks. Survival analyses (progression-free survival [PFS], overall survival), radiological response assessment, toxicity assessment, and health-related quality of life (QoL) was performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Overall, 26 patients completed 4 cycles, and 4 patients had less than 4 cycles of <jats:sup>177<\/jats:sup>Lu-DOTATATE. One patient (3%) did not complete treatment because of hematological toxicity. The estimated median PFS and median overall survival were calculated at 27 and 35 months, respectively. End-of-treatment radiological assessment showed partial response in 5 patients (17%), stable disease in 20 patients (66%), and radiological progressive disease in 3 patients (10%). Clinical progression was seen in a further 2 patients (7%).<\/jats:p>\n            <jats:p>The incidence of grade 3\/4 bone marrow toxicity was 10%. No patient had grade 3\/4 peptide receptor radionuclide therapy\u2013related nephrotoxicity. There was overall improvement in global QoL score (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire\u2014Gastrointestinal NET-21) (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.019)<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>\n                                 <jats:sup>177<\/jats:sup>Lu-DOTATATE seems to have satisfactory therapeutic outcome in patients with advanced metastatic NET with extensive bone disease, with reasonable PFS and significant improvement in the global health-related QoL. The bone marrow toxicity was within the accepted range. Increasing the interval between cycles does not seem to reduce efficacy and may reduce toxicity, ensuring the bone marrow has sufficient time to recover between cycles.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000004671","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T18:01:10Z","timestamp":1683828070000},"page":"667-672","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Safety and Efficacy of 177Lu-DOTATATE in Neuroendocrine Tumor Patients With Extensive Bone Disease"],"prefix":"10.1097","volume":"48","author":[{"given":"Shahad","family":"Alsadik","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopinath","family":"Gnanasegaran","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luohai","family":"Chen","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Marie","family":"Quigley","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalvinder","family":"Mandair","sequence":"additional","affiliation":[{"name":"Neuroendocrine Tumour Unit, Royal Free London NHS Foundation Trust, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Toumpanakis","sequence":"additional","affiliation":[{"name":"Neuroendocrine Tumour Unit, Royal Free London NHS Foundation Trust, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyn","family":"Caplin","sequence":"additional","affiliation":[{"name":"Neuroendocrine Tumour Unit, Royal Free London NHS Foundation Trust, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaunak","family":"Navalkissoor","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"issue":"suppl 4","key":"bib1-20250621","first-page":"iv293","article-title":"Management of neuroendocrine tumours","volume":"15","year":"2004","journal-title":"Ann Oncol"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/annonc\/mdq022","article-title":"Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE)","volume":"21","year":"2010","journal-title":"Ann Oncol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"121","year":"2015","journal-title":"Cancer"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1002\/ijc.30400","article-title":"The epidemiology of metastases in neuroendocrine tumors","volume":"139","year":"2016","journal-title":"Int J Cancer"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1530\/EC-14-0119","article-title":"Bone metastases and skeletal-related events from neuroendocrine tumors","volume":"4","year":"2015","journal-title":"Endocr Connect"},{"key":"bib7-20250621","first-page":"1602","article-title":"Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy","volume":"40","year":"1999","journal-title":"J Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1677\/erc.1.01017","article-title":"Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization","volume":"12","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1677\/ERC-08-0301","article-title":"Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma","volume":"16","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3390\/cancers11091332","article-title":"Bone metastases in neuroendocrine neoplasms: from pathogenesis to clinical management","volume":"11","year":"2019","journal-title":"Cancers (Basel)"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2967\/jnumed.111.090373","article-title":"Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate","volume":"52","year":"2011","journal-title":"J Nucl Med"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.2015.64.0987","article-title":"Prospective study of 68Ga-DOTATATE positron emission tomography\/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib13-20250621","first-page":"529","article-title":"Bone metastases in neuroendocrine tumors","volume":"118","year":"2017","journal-title":"Bratisl Lek Listy"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"bib15-20250621","first-page":"437","article-title":"Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis","volume":"3","year":"2013","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1)","volume":"45","year":"2009","journal-title":"Eur J Cancer"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-DOTATATE for midgut neuroendocrine tumors","volume":"376","year":"2017","journal-title":"N Engl J Med"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2967\/jnumed.113.125336","article-title":"Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate","volume":"55","year":"2014","journal-title":"J Nucl Med"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"e13210","DOI":"10.1111\/jne.13210","article-title":"Single centre retrospective review of outcome of 177Lu-DOTATATE peptide receptor radionuclide therapy in the treatment of progressive metastatic neuroendocrine tumours: survival, toxicity, and prognostic factors","volume":"34","year":"2022","journal-title":"J Neuroendocrinol"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3413\/Nukmed-0614-13-08","article-title":"Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement","volume":"53","year":"2014","journal-title":"Nuklearmedizin"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000508633","article-title":"Bone metastases in neuroendocrine tumors: molecular pathogenesis and implications in clinical practice","volume":"111","year":"2021","journal-title":"Neuroendocrinology"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","year":"2017","journal-title":"Clin Cancer Res"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00259-013-2677-3","article-title":"Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1\/2 pancreatic neuroendocrine tumours","volume":"41","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s00259-016-3533-z","article-title":"Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-DOTATATE","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/MNM.0000000000000874","article-title":"177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update","volume":"39","year":"2018","journal-title":"Nucl Med Commun"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000506746","article-title":"177Lu-DOTATATE therapy of advanced pancreatic neuroendocrine tumors heavily pretreated with chemotherapy: analysis of outcome, safety, and their determinants","volume":"111","year":"2021","journal-title":"Neuroendocrinology"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2967\/jnumed.117.189712","article-title":"Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","article-title":"Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004671","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:06:46Z","timestamp":1750532806000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004671","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,11]]}}}